Trial reportHematological oncology2018
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.
Trial report in Hematological oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient-Reported Outcome Measures (PROMS) in Lymphoma.Current oncology (Toronto, Ont.) · 2025Pooled it
- Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma.Journal of the National Cancer Institute · 2025Trial
- Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.Annals of hematology · 2025Trial
- Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP.Annals of hematology · 2024Trial
- Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.Bone marrow transplantation · 2017Trial
- Article
- Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: a longitudinal registry-based analysis.Blood advances · 2025Article
- Patient-reported symptom burden and health-related quality of life in patients with aggressive Non-Hodgkin lymphoma: a cross-sectional study.BMC cancer · 2025Article
- A prospective evaluation of quality of life, psychosocial distress, and functional outcomes two years after radical cystectomy and urinary diversion in 842 German bladder cancer patients.Journal of cancer survivorship : research and practice · 2025Article
- Psychosocial distress and quality of life in patients after radical cystectomy - one year follow-up in 842 German patients.Journal of cancer survivorship : research and practice · 2024Article
- Using three-dimensional model-based tumour volume change to predict the symptom improvement in patients with renal cell cancer.3 Biotech · 2024Article
- Quality of Life and Survivorship in Lymphoma.Current oncology reports · 2022Review
- Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis.JCO oncology practice · 2022Article
- Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study.Oncology and therapy · 2022Article
- Article
- The association of health behaviors with quality of life in lymphoma survivors.Leukemia & lymphoma · 2021Article
- Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overall survival (OS). QOL was measured with the Functional Assessment of Cancer Treatment-General (FACT-G), which measures 4 domains: physical, social/family, emotional, and functional well-being (WB); a single item Linear Analogue Self-Assessment (LASA) measuring overall QOL; and a spiritual WB LASA. From 9/2002 to 12/2009, 701 patients with aggressive lymphoma who completed baseline QOL questionnaires were enrolled. At a median follow-up of 71 months (range 6-128), 316 patients (45%) had an event and 228 patients (33%) died. All baseline QOL measures but emotional WB were significantly associated with OS (all P < 0.04); of which all but LASA spiritual remained significant after adjusting for IPI and NHL subtype. The strongest associations were with total FACT-G (adjusted HR = 0.86, 95% CI: 0.79-0.94, P = 0.00062) and functional WB (adjusted HR = 0.88, 95% CI: 0.83-0.93, P < .0001). QOL LASA was associated with OS (adjusted HR = 0.92, 95% CI: 0.87-0.97, P = 0.0041). Patients with clinically deficient QOL (overall QOL ≤50) had a median OS of 92 months compared with 121 months for patients with QOL >50 (P = 0.0004). In this large sample of patients with aggressive lymphoma, we found that baseline QOL is independently predictive of OS. QOL should be assessed as a prognostic factor in patients with aggressive lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.